What is UBM Technology and How Does it Work?
ACell’s proprietary urinary bladder matrix (UBM) technology platform is based on an extracellular matrix, or ECM, derived from porcine urinary bladder.
ACell’s proprietary method of processing this raw material results in products that are differentiated from other competitive ECM products because they include an intact epithelial basement membrane on one surface and a lamina propria layer on the opposite surface. MatriStem devices contain multiple types of carbohydrates, collagens, proteins and other components, and are gradually resorbed by the patient following implantation.
These product characteristics facilitate a constructive remodeling process in the body that reduces scarring and facilitates the restoration of normal site-appropriate tissue. These features represent key competitive advantages over other treatment modalities and offer new application paradigms for many wound care procedures and surgical repairs.
As a result, ACell’s products are often used in complex slow-healing wounds or surgical procedures where leading competitive regenerative therapy treatments have not been effective.
What is an Extracellular Matrix (ECM)?
Extracellular Matrix (ECM) technology is the scaffold on which new tissue growth is constructed. It is the structure that makes new tissue regeneration possible.
Extracellular matrices come from various sources, such as artificial materials (synthetics), processed from animals (xenografts), or donated from humans (allografts).
Synthetic wound and surgical products were initially developed to help the body heal itself through scarring. Even with the development of synthetic products, slow-healing and non-healing wounds and surgically-treated soft tissue deficits remained difficult to heal, which led to the development and introduction of biologically-derived scaffolds.
MatriStem is the only commercially available ECM made of urinary bladder matrix (UBM). It facilitates the body’s own regenerative capabilities and helps restore normal site-appropriate tissue, which we believe addresses the limitations of the existing regenerative medicine products.